文献速递泌尿生殖介入PETCT

68Ga前列腺特异性膜抗原PET/CT引导机器人辅助经臀前列腺活检的安全性与诊断效能

Safety and Diagnostic Yield of 68Ga Prostate-specific Membrane Antigen PET/CT-guided Robotic-assisted Transgluteal Prostatic Biopsy.
PubMed 文献 · Radiology · 2022-02-22

本单中心非随机前瞻性试验纳入78例临床怀疑前列腺癌(血清前列腺特异性抗原>4 ng/mL)的参与者,评估68Ga PSMA PET/CT引导机器人臂辅助经臀前列腺活检的安全性与诊断效能。56例(72%)存在PSMA高摄取前列腺内病灶者接受靶向活检,前列腺癌确诊率为96%(54/56),临床显著前列腺癌(Gleason评分≥7)占44%(24/54);术后并发症9%(5/56)且均为轻微,无感染发生。

要点

  • PSMA高摄取病灶靶向活检的前列腺癌确诊率达96%(54/56)。
  • 临床显著前列腺癌(Gleason评分≥7)占确诊者的44%(24/54)。
  • 术后并发症轻微(9%,5/56),无术后感染。

核心结论

  • 经臀PSMA PET/CT引导机器人靶向前列腺活检对PSMA高摄取病灶安全且前列腺癌诊断效能高。

研究设计与样本

  • 单中心非随机前瞻性试验,2019年1月至2020年9月招募78例临床怀疑前列腺癌(血清PSA>4 ng/mL)的参与者,先行全身68Ga PSMA PET/CT,对存在PSMA高摄取前列腺内病灶者行机器人臂辅助经臀靶向活检,记录并发症与组织病理结果,疼痛用视觉模拟量表评分。

关键影像表现/征象

  • 56例(72%)参与者存在PSMA高摄取前列腺内病灶并接受靶向活检,其中22例(39%)既往经直肠超声引导活检阴性。
  • 54/56(96%)参与者确诊前列腺癌,其中24/54(44%)为临床显著前列腺癌(Gleason评分≥7)。
  • 2例参与者样本不具代表性,需再次活检。

诊断标准与关键数值

  • 以组织病理学为参考标准,PSMA高摄取病灶靶向活检的前列腺癌确诊率为96%(54/56)。
  • 临床显著前列腺癌定义为Gleason评分≥7,占确诊者的44%(24/54)。
  • 入组标准为临床怀疑前列腺癌且血清PSA>4 ng/mL。

临床应用与阅片要点

  • 对PSMA高摄取的前列腺内病灶可行机器人臂辅助经臀靶向活检,包括既往经直肠超声引导活检阴性者。
  • 所有参与者术中均有疼痛,轻度(中位VAS评分1,四分位距1-2)占64%(36/56),中度(中位VAS评分5,四分位距5-6)占36%(20/56)。
  • 术后并发症均为轻微:血尿4例、血精1例、臀部疼痛2例,无术后感染。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Transrectal US-guided biopsy with or without MRI fusion is performed for diagnosing prostate cancer (PCa) but has limitations. Gallium 68 (68Ga) prostate-specific membrane antigen (PSMA) PET/CT-guided targeted biopsy has the potential to improve diagnostic yield of PCa. Purpose To evaluate the safety and diagnostic yield of 68Ga PSMA PET/CT-guided, robotic-arm assisted transgluteal prostatic biopsy. Materials and Methods In this single-center nonrandomized prospective trial, participants with a clinical suspicion of PCa (serum prostate-specific antigen level > 4 ng/mL) were recruited from January 2019 to September 2020. After whole-body 68Ga PSMA PET/CT, participants with PSMA-avid intraprostatic lesions underwent PET-guided transgluteal biopsy by using an automated robotic arm. To assess safety and diagnostic yield, procedure-related complications and histopathologic results were documented. Pain during the procedure was scored by a visual analog scale. Descriptive statistics were applied; qualitative variables were reported in percentages. Results Seventy-eight participants (mean age, 66 years ± 7 [standard deviation]; 36 participants [46%] with prior negative results at transrectal US-guided biopsy) were enrolled. Fifty-six (72%) participants had PSMA-avid lesions (prior negative results at transrectal US-guided biopsy in 22 of 56 [39%]) and underwent targeted biopsy. PCa was confirmed in 54 of 56 (96%) participants, and clinically significant PCa (Gleason score ≥ 7) was confirmed in 24 of 54 (44%). Two participants had nonrepresentative samples that required rebiopsy. All participants experienced pain during the procedure, mild (median visual analog scale score, 1; interquartile range, 1-2) in 36 of 56 (64%) and moderate (median visual analog scale score, 5; interquartile range, 5-6) in 20 of 56 (36%). Postprocedure complications were noted in five of 56 (9%) participants and were minor (hematuria, four participants; hematospermia, one participant; and gluteal pain, two participants). No participant developed a postprocedural infection. Conclusion Transgluteal prostate-specific membrane antigen (PSMA) PET/CT-guided, robotic-targeted prostatic biopsy is safe with a high diagnostic yield of prostate cancer for PSMA-avid lesions. Clinical trial registration no. NCT05022576 © RSNA, 2022.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Kumar, Singh, Mittal, et al. Safety and Diagnostic Yield of 68Ga Prostate-specific Membrane Antigen PET/CT-guided Robotic-assisted Transgluteal Prostatic Biopsy. Radiology. 2022. PMID: 35191735. doi:10.1148/radiol.204066

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。